(Q36360350)

13 August 2017

1 reference

title

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia (English)

1 reference

13 August 2017

1 reference

2

Gillian M Keating

1 reference

13 August 2017

Paul L McCormack

1

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

65

1 reference

13 August 2017

18

1 reference

13 August 2017

2719-2740

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565180-00014

13 August 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Treating Dyslipidemic Patients with Lipid‐Modifying and Combination Therapies

1 reference

12 December 2020

Management of dyslipidaemia

1 reference

12 December 2020

Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety

1 reference

12 December 2020

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

12 December 2020

Evaluating niacin in its various forms.

1 reference

12 December 2020

New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.

1 reference

12 December 2020

Diabetic dyslipidemia

1 reference

12 December 2020

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

12 December 2020

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis

1 reference

12 December 2020

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

1 reference

12 December 2020

Niacin for dyslipidemia: considerations in product selection.

1 reference

12 December 2020

Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial.

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

1 reference

12 December 2020

Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group

1 reference

12 December 2020

Optimal therapy of low levels of high density lipoprotein-cholesterol

1 reference

12 December 2020

New perspectives on the use of niacin in the treatment of lipid disorders

1 reference

12 December 2020

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

1 reference

12 December 2020

A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women

1 reference

12 December 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

12 December 2020

Effects of extended-release niacin on lipoprotein subclass distribution

1 reference

12 December 2020

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

12 December 2020

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

1 reference

12 December 2020

Understanding niacin formulations

1 reference

12 December 2020

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

1 reference

12 December 2020

Antiatherothrombotic effects of nicotinic acid

1 reference

12 December 2020

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

12 December 2020

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

1 reference

12 December 2020

Treatment of hyperlipidemia with combined niacin-statin regimens

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

1 reference

12 December 2020

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

1 reference

12 December 2020

Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia

1 reference

12 December 2020

Evidence-based guidelines for cardiovascular disease prevention in women

1 reference

12 December 2020

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

1 reference

12 December 2020

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

12 December 2020

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.

1 reference

12 December 2020

10.2165/00003495-200565180-00014

Identifiers

DOI

1 reference

PubMed ID

16392885

Dimensions Publication ID

13 August 2017

0 references

1 reference

PubMed ID

16392885